Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|10|1654-1661

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.10, 2015-05, pp. : 1654-1661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 348-353

Karger

Access to resources Recommend Favorite

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-06 ,pp. : 571-576

Karger

Access to resources Recommend Favorite

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 66-71

Karger

Access to resources Recommend Favorite

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 583-590

Karger

Access to resources Recommend Favorite

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3412-3421

John Wiley & Sons Inc

Access to resources Recommend Favorite